Tasly Pharmaceutical Group Co., Ltd
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS13
PHASE 3 / 2-39
RECRUITING8
READOUTS ≤12 MONTHS7
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Antiwei Granules NCT06697886 |
P3 | Recruiting | Common Cold | 480 | 2025-06-25 |
| Xiang Ju Ru Pi Ning capsule NCT06685978 |
P3 | Recruiting | Hyperplasia of Mammary Glands | 430 | 2026-04-30 |
| Changkang granules NCT06753890 |
P3 | Not yet recruiting | Diarrhea-predominant Irritable Boewl Syndrome | 520 | 2026-11-11 |
| Jitongning tablets NCT06000956 |
P3 | Recruiting | Ankylosing Spondylitis | 408 | 2026-12-01 (+16 mo) |
| Low dose Jia Shen Tablet NCT06669169 |
P2 | Not yet recruiting | Heart Failure | 288 | 2026-12-31 |
| Lianxiaxiaopi Granules NCT06696261 |
P3 | Recruiting | Postprandial Distress Syndrome | 342 | 2026-12-31 (+7 mo) |
| JS1-1-01 low-dose group NCT07485595 |
P2/3 | Not yet recruiting | Depression | 180 | 2026-12-31 |
| Mesenchymal stem cells(HucMSCs) NCT07265349 |
P1/2 | Recruiting | Coronary Artery Bypass Grafting (CABG); Chronic Heart Failure | 51 | 2026-12-31 |
| Susu Xiao'er Zhike Granules NCT06773117 |
P3 | Not yet recruiting | Cough | 360 | 2027-05-31 (+14 mo) |
| B2065 NCT07371624 |
P1/2 | Recruiting | Acute Ischemic Stroke | 54 | 2027-12 |
| P134 cell injection NCT07318818 |
P1/2 | Recruiting | Recurrent Glioblastoma IDH Wildtype | 26 | 2028-02-29 |
| Qishen Yiqi Dripping Pills 2 bags NCT07687186 |
P3 | Recruiting | Heart Failure | 636 | 2028-06-22 |
| NCT07269769 NCT07269769 |
P3 | Not yet recruiting | AMD | 450 | 2031-12-31 |